Peginterferon alfa-2a (40KD) (PEGASYSÆ) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose

Professor Stephanos J. Hadziyannis

Department of Medicine and Hepatology

Henry Dunant Hospital

Athens, Greece

Next slide

Back to first slide

View graphic version